BOCOM International Raises AKESO Target Price to HK$183, Maintains "Buy" Rating

Stock News

2025/08/28

BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical significance. The firm indicated it has raised its overseas peak-of-sales forecast to $16.5 billion.

The firm has adjusted its financial projections for the group from 2025 to 2027, while raising the target price from HK$140 to HK$183, maintaining a "Buy" rating.

According to the report, the company's commercial sales revenue in the first half grew 49% year-over-year to RMB 1.4 billion, primarily driven by the formal inclusion of core bispecific antibody products Kadcyla and Ivonescimab in the national reimbursement catalog at the beginning of the year, alongside the commercial launch of PCSK9 and IL12/IL23.

The company's sales team now exceeds 1,200 personnel and continues to strengthen its oncology and specialty pharmaceutical business divisions.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1132796683"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132796683\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132796683?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 17:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132796683","market":"fut","top_or_hot":-1,"title":"BOCOM International Raises AKESO Target Price to HK$183, Maintains \"Buy\" Rating","media":"Stock News","content":"<p>BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical significance. The firm indicated it has raised its overseas peak-of-sales forecast to $16.5 billion.</p>\n<p>The firm has adjusted its financial projections for the group from 2025 to 2027, while raising the target price from HK$140 to HK$183, maintaining a \"Buy\" rating.</p>\n<p>According to the report, the company's commercial sales revenue in the first half grew 49% year-over-year to RMB 1.4 billion, primarily driven by the formal inclusion of core bispecific antibody products Kadcyla and Ivonescimab in the national reimbursement catalog at the beginning of the year, alongside the commercial launch of PCSK9 and IL12/IL23.</p>\n<p>The company's sales team now exceeds 1,200 personnel and continues to strengthen its oncology and specialty pharmaceutical business divisions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BOCOM International Raises AKESO Target Price to HK$183, Maintains \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBOCOM International Raises AKESO Target Price to HK$183, Maintains \"Buy\" Rating\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-08-28 17:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical significance. The firm indicated it has raised its overseas peak-of-sales forecast to $16.5 billion.</p>\n<p>The firm has adjusted its financial projections for the group from 2025 to 2027, while raising the target price from HK$140 to HK$183, maintaining a \"Buy\" rating.</p>\n<p>According to the report, the company's commercial sales revenue in the first half grew 49% year-over-year to RMB 1.4 billion, primarily driven by the formal inclusion of core bispecific antibody products Kadcyla and Ivonescimab in the national reimbursement catalog at the beginning of the year, alongside the commercial launch of PCSK9 and IL12/IL23.</p>\n<p>The company's sales team now exceeds 1,200 personnel and continues to strengthen its oncology and specialty pharmaceutical business divisions.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348783233.USD","symbol_name":"安聯東方收入型 CI A Dis美元","start_time":0,"source_url":"","article_id":"1132796683","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132796683","pubTimestamp":1756374056,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0348783233.USD":"安联东方收入型 CI A Dis美元","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU1720050803.USD":"安联全方位中国股票基金","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","09926":"康方生物","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","BK1161":"生物科技","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","BK1574":"生物医药B类股","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC"},"translate_title":"交银国际上调康方生物目标价至183港元维持“买入”评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"BOCOM International released a research report stating that given the larger sample size of AKESO's (09926) HARMONi study, the final analysis of overall survival (OS) is likely to achieve statistical significance. The firm indicated it has raised its overseas peak-of-sales forecast to $16.5 billion.\nThe firm has adjusted its financial projections for the group from 2025 to 2027, while raising the target price from HK$140 to HK$183, maintaining a \"Buy\" rating.\nAccording to the report, the company's commercial sales revenue in the first half grew 49% year-over-year to RMB 1.4 billion, primarily driven by the formal inclusion of core bispecific antibody products Kadcyla and Ivonescimab in the national reimbursement catalog at the beginning of the year, alongside the commercial launch of PCSK9 and IL12/IL23.\nThe company's sales team now exceeds 1,200 personnel and continues to strengthen its oncology and specialty pharmaceutical business divisions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}